Kisunla is a medicine for treating adults with mild cognitive impairment (memory and thinking problems) and mild dementia due to Alzheimer’s disease (early Alzheimer’s disease). It is for people who have only one or no copy of a gene called the apolipoprotein E4 (ApoE4) and who have an abnormal build-up of protein deposits known as amyloid beta plaques in the brain. Kisunla contains the active substance donanemab.
Therapeutic Indication
### Therapeutic indication Donanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology (see section 4.4).
Therapeutic Area (MeSH)
ATC Code
N06DX05
ATC Item
donanemab
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| donanemab | N/A | 多奈单抗 |
EMA Name
Kisunla
Medicine Name
Kisunla
Aliases
N/ANo risk management plan link.
